WEBINAR: High-throughput flow cytometry-based platform for interrogation of genetically-modified lymphocytes: a rapid and efficient method for assessing anti-tumor response


Tamara J. Laskowski, Ph.D.
MD Anderson Cancer Center, USA | Senior Research Scientist


The remarkable discovery that one’s own immune system can become a powerful weapon against cancer has changed the oncology landscape. Immune checkpoint blockade, augmentation of tumor infiltrating lymphocyte (TIL) function, and genetic engineering of tumor-targeting CAR T- and NK cells are all immunotherapy strategies which have led to unprecedented results in human trials.  This immense progress has fostered a greater need for technologies that can support the growing requirements of the field in an efficient, time and cost-permissive manner. As an immunotherapy group focusing on both CAR-T and CAR-NK development for hematological and solid malignancies, we sought to address this need. Through a combination of high-throughput flow cytometry and live-cell imaging approaches, we built platforms that allow for simultaneous assessment of immune-cell activation and tumor cell cytotoxicity. This new multi-parametric approach provides greater insight into the biological features associated with specific genetic modifications present in the lymphocytes and allows for better understanding of the kinetics of lymphocyte-mediated anti-tumor activity.

Learn more about Sartorius solutions for CAR-T Discovery & Development at www.sartorius.com/car-t-research.

Complete the form below to watch the webinar.

Are you interested in receiving more information on cell analysis instruments for your research?

Are you looking to purchase cell analysis equipment for your lab?

What other products/areas are of interest (check all that apply):

How can we assist you with these products?